Overview
Genomic Testing Cooperative (GTC) provides comprehensive DNA and RNA next-generation sequencing (NGS) for solid tumors and hematologic malignancies, including liquid biopsy options. Their cooperative model partners with labs, hospitals, and oncology practices to share resources, reduce costs, and enable faster turnaround times of 5-10 days using AI-driven informatics. Tests are Medicare-covered, with reporting including therapy recommendations and clinical trial matches.
Frequently asked questions
- What testing capabilities does GTC offer?
- GTC offers comprehensive genomic profiling with DNA and RNA NGS panels for solid tumors, hematologic neoplasms, liquid biopsies, and CSF, including fusion detection, alternative splicing, gene expression, and AI-enhanced reporting with therapy and trial recommendations.
- What is GTC's cooperative model and service options?
- GTC's co-op model allows partners to select services like in-house genomics labs managed by GTC, cooperative associate, or reference lab, sharing resources, expertise, and big data for innovation while localizing cancer care.
- What are GTC's turnaround times and coverage?
- Turnaround time is 5-10 days. All tests are well-validated and covered by Medicare, with direct insurance billing handled by GTC including appeals.